Related Experiment Videos
Somatostatin receptor expression in Hürthle cell cancer of the thyroid
S A Gulec1, A N Serafini, K S Sridhar
1Division of Nuclear Medicine, University of Miami School of Medicine Department, Florida, USA.
Abstract:
Somatostatin receptor expression, which was not a previously described marker for Hürthle cell cancer of the thyroid, was demonstrated by in vivo imaging with (111)In-pentetreotide in three patients. This phenomenon not only adds another imaging technique to the nuclear medicine armamentarium for detecting recurrent and metastatic cancer in patients with Hürthle cell cancer but also opens up an alternative therapeutic avenue with somatostatin analogs or their radiolabeled compounds.
Insights
Somatostatin receptor expression was detected in Hürthle cell cancer using in vivo imaging. This finding offers new diagnostic and therapeutic strategies for this rare thyroid cancer.
Area of Science:
- Endocrinology
- Nuclear Medicine
- Oncology
Background:
- Hürthle cell cancer of the thyroid is a rare malignancy.
- Diagnostic and therapeutic options for recurrent or metastatic disease are limited.
- Somatostatin receptor expression has not been previously established as a marker for this cancer.
Observation:
- In vivo imaging with (111)In-pentetreotide was performed in three patients with Hürthle cell cancer.
- The study aimed to investigate somatostatin receptor expression in this specific cancer type.
Findings:
- Somatostatin receptor expression was successfully demonstrated in Hürthle cell cancer using (111)In-pentetreotide imaging.
- This represents a novel imaging marker for Hürthle cell cancer.
Implications:
- This finding introduces a new nuclear medicine imaging technique for detecting recurrent and metastatic Hürthle cell cancer.
- It also suggests potential therapeutic applications using somatostatin analogs or radiolabeled compounds.